Participants and assessment teams were allocated under a blinded, controlled design.

Randomised, double-blind

DESIGN

Changes in the intervention group are compared with a placebo group according to the SOP of the trial.

Placebo controlled

COMPARATOR

Baseline and post-intervention assessments support within- and between-group analysis.

Twelve months

DURATION

The programme focused on 260 adult volunteers meeting the study eligibility criteria at BSMMU, Dhaka, Bangladesh.

Healthy Adults

POPULATION

Biological and participant-reported outcomes

The programme combines biomarker assessment with general health and wellbeing measures. The presence of a measurement does not itself establish efficacy.

TREC analysis

Blood counts and selected immune-cell parameters were evaluated at defined study timepoints.

01

Blood measurements

T-cell receptor excision circles were assessed as a laboratory marker relevant to recent thymic output

02

Participant-reported measures

Questionnaires captured areas such as pain, energy, sleep, stress, urinary health, mood swings, skin healths, quality of life etc.

03

Safety and tolerability

Participant experience and relevant safety information formed part of the study oversight.

04

STUDY JOURNEY

From protocol to scientific interpretation

T-Booster has completed participant involvement of two trials over 12-month randomised, double-blind, placebo-controlled study.

RESULT STATUS

Initial analysis of T-Booster study

Participant involvement is complete. Final laboratory analysis and scientific interpretation are being finalised for scientific publications

INITIAL ANALYSIS BEFORE AFTER TAKING T-BOOSTER

CBC analysis shows significant inprovement

Questionnaire before and after signingficant improment

INITIAL Analysis revel trec dna is over 48% increase

WHY THE THYMUS MATTERS

A vital part of the immune system that changes with age

The thymus is where T cells develop and mature, helping coordinate the body’s adaptive immune defences. These cells recognise pathogens, destroy virus-infected cells and help identify abnormal cells, including some cancer cells. As the thymus naturally becomes less active with age, the production and diversity of new T cells gradually declines.

Immune-cell development

The thymus is an important site for the maturation and selection of T cells.

Age-related change

Thymus functions reduce over time, making an important area of research.

A nutritional research opportunity

T-Booster explores natural formulation to support immune-health measures.

Learn about our scientific approach

01

02

03

Age-related thymus shrinkage accelerates immune ageing

• Reduces T cell production, weakening immunity.

• Increases susceptibility to infections.

• Lowers immune surveillance, raising cancer risk.

• Triggers immune dysregulation, leading to autoimmune diseases.

• Elevates mortality risk from severe infections like COVID-19.

• Reduces T cell diversity, slowing recovery and vaccine response.

• Speeds the onset of age-related conditions.

• Limits immune memory due to fewer naive T cells.

THE CHALLENGE OF HEALTHY AGEING

WHAT IS T-BOOSTER

Designed to address age-related decline in thymus function

Inspired by decades of research into the thymus and immune ageing, T-Booster is a next-generation nutritional formulation combining carefully selected vitamins, minerals and nutraceutical ingredients.

Developed by drug discovery scientists Dr Md Arif Sheikh and Dr David Brown, T-Booster is designed to enhance immune function through a science-led, evidence-based approach and has been evaluated in human clinical research.

CLINICAL STUDY

Led by people who understand drug discovery

FOUNDER & CEO

Dr Md Arif Sheikh, PhD

Molecular and structural biologist with more than 19 years of experience across drug discovery, protein science and biotechnology innovation.

DRUG DISCOVERY ADVISOR

Dr David Brown, PhD, FSRM

Experienced drug discoverer (Inventor of viagra) and biotechnology advisor contributing strategic scientific insight to the T-Booster development programme.

INVESTORS & PARTNERSHIPS

Building the route from research to global commercialisation

We welcome conversations with strategic investors, distribution partners, scientific collaborators and experienced consumer-health operators.

FREQUENTLY ASKED QUESTIONS

Clear answers about the our T-Booster

Scientific and commercial information will be updated as final analysis, scientific paper, patent, trademark, regulatory review and launch preparation progress.

Is T-Booster available to buy?

T-Booster commercial launch in end of 2006. Join the early-access list for confirmation.

Has the human study finished?

Participant involvement has completed. Scientific interpretation are being finalised.

What does T-Booster claim to do?

The product is being positioned for responsible immune-health support as a supplement.

Is this medical treatment?

No. T-Booster is a food supplement and is not intended to treat, cure or prevent disease.

EARLY ACCESS

Be among the first to hear about T-Booster

Receive product-development news, scientific updates and confirmed launch information.